Harvard Bioscience

Harvard Bioscience reported Q2 2026 revenue of $22.7m (+11%) and a gross profit of $12.6m; adjusted loss per share was a much smaller-than-expected -$0.14 (expected -$0.38). The company raised its full-year guidance: revenue growth 3–5%, adjusted gross margin 57–59%, and adjusted EBITDA growth 6–10%. For Q3 Harvard Bioscience expects revenue of $21.0–22.6m and adjusted EBITDA of $1.5–2.5m. Despite a net loss of $2.9m in the quarter, adjusted EBITDA improved to $1.7m and the H1 net loss narrowed significantly to $6.3m due to last year’s goodwill impairment. » More on de.investing.com

Harvard Bioscience reported a loss of $0.33 per share for Q1 2026 versus expected -$0.005 and revenue of $20.8 million versus a projected $21.25 million. Gross margin improved to 59% and GAAP operating loss fell to $1.2 million from $49.7 million a year earlier. The stock briefly rose 3.75% in trading but fell 9.36% in premarket trading, reflecting investor uncertainty. Management is targeting a gross margin above 60% and double‑digit revenue growth from product innovations for 2026 and is relying on efficiency measures such as "Project Viking." » More on de.investing.com

Harvard Bioscience presented its strategy at the KeyBanc forum: a focus on organoid- and bioproduction-related growth areas and the product launch of a cGMP product in the second half of the year. A refinancing reduces annual debt service over the next two years from $8 million to $5 million; the “Viking” project targets $4 million in cost savings and an EBITDA margin in the low 20 percent range. Other drivers include new distribution agreements (including Fisher Scientific), an expected recovery of the China business in Q2 2026, and a doubling of the revenue contribution from new products to 10%. » More on de.investing.com